Overview
SNDX market data
Price History
SNDX price chart · 1M
- O
- 19.89
- H
- 20.13
- L
- 19.76
- C
- 20.12
- Vol
- 24,866.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $19.89
- Previous Close
- $20.09
- Day High
- $20.13
- Day Low
- $19.76
- 52 Week High
- $25.20
- 52 Week Low
- $16.67
- 7 Day Return
- +1.87%
- 30 Day Return
- +2.50%
- 90 Day Return
- +2.71%
- 1 Year Return
- -2.47%
- Daily Notional Volume
- $500.3K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.29 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.42 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -87.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $12.99 – $25.59 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.7B · P/B 28.25 · P/S 6.91.
Company News
UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $33Benzinga · Aug 21, 2026, 3:44 PM
JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Lowers Price Target to $40Benzinga · Aug 11, 2026, 2:48 PM
Syndax Pharmaceuticals shares are trading lower after the company reported mixed Q2 financial results. Also, HC Wainwright & Co. lowered its price target on the stock from $40 to $38.Benzinga · Aug 5, 2026, 1:00 PM
HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $38Benzinga · Aug 5, 2026, 11:10 AM
Syndax Pharmaceuticals Q2 EPS $(0.55) Misses $(0.49) Estimate, Sales $72.788M Miss $79.323M EstimateBenzinga · Aug 4, 2026, 8:03 PM
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price TargetBenzinga · Jul 15, 2026, 10:29 AM
8-K filing — Syndax Pharmaceuticals Inc (SNDX)SEC EDGAR · Jul 14, 2026, 12:30 PM
Syndax Presents Key Revuforj Data In Multiple Acute Leukemia Subtypes And Settings At EHA 2026 CongressBenzinga · Jun 11, 2026, 11:11 AM
Syndax Announces Publication Of Phase 1/2 SAVE Trial Data Of All-Oral Regimen Of Revuforj, Decitabine/Cedazuridine, And Venetoclax In R/R NPM1m, KMT2Ar, or NUP98r AML In Journal Of Clinical OncologyBenzinga · Jun 11, 2026, 11:09 AM
Syndax Pharma Enters Into Privately Negotiated Subscription Agreements For Issuance Of $250M Aggregate Principal Amount Of 2.25% Convertible Senior Notes Due 2031Benzinga · Jun 4, 2026, 11:20 AM